Insurance Verification Without Limits
Unlock the Power of ICV All-Payer
Integrated Coverage Validation (ICV) All-Payer transforms insurance verification by proactively catching coverage issues before claims are sent. It prevents costly denials and gives you a more complete financial picture up front.
Smarter Coverage Validation Starts Here
Connecting Your Revenue Cycle to Every Payer
Stop playing catch-up with payer-specific validations. Quadax’s ICV All-Payer brings comprehensive coverage validation to the forefront of your revenue cycle, giving you unmatched visibility and control across Medicare, Medicaid (expanded to 49 states), Blue Cross, Blue Shield, and Commercial payers—all through one revolutionary platform that connects Electronic Eligibility Verification and ICV Edit engines for unprecedented efficiency.
Why ICV All-Payer?
Complete Payer Coverage, Zero Gaps
Automatically validate eligibility across all supported payers—from Medicare to 49 states of Medicaid, Blues, and Commercial Payers—without separate licenses or complex configurations.
Revolutionary Technology Integration
Our groundbreaking connection between the Electronic Eligibility Verification and ICV Edit Engines delivers enhanced efficiency, standardization, clearer error codes, and condensed validation logic.
Seamless for Legacy Clients
Existing ICV-Medicare or ICV-Medicaid users retain full functionality while gaining massive Medicaid expansion to 49 states, supported by proactive monitoring.
Unified Management Interface
The updated Xpeditor Settings screen centralizes all payer edit controls, streamlining workflows by eliminating the need for multiple systems or manual HMO configurations.
Future-Ready Flexibility
Built on Quadax’s scalable platform, ICV All-Payer provides the foundation for future intelligent automation and advanced features.
Enhanced Control Settings
The updated ICV Settings screen will offer enhanced control, allowing intuitive options to exclude specific payers and fine-tune workflows using existing Payer Matching settings.
From Denials to Dollars: The ICV All-Payer Advantage
